QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
Last trade$10.04
Day change-$0.17 (-1.67%)
Day range$9.97 – $10.87
Volume894,964
Market cap$701M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$700.53M
Price / earnings
—
Price / book
0.39×
Price / sales
0.27×
EV / sales
1.34×
EV / EBITDA
8.82×
Profitability
Earnings per share
-$5.38
Return on assets
-6.39%
Return on equity
-20.61%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.64×
Current ratio
1.36×
Quick ratio
0.75×
Cash ratio
0.16×
Cash flow
Price / cash flow
88.68×
Price / free cash flow
—
Free cash flow
-$117.9M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for QDEL, quarterly periods
Line item
Q3 FY2026 Sep 27, 2026
Q2 FY2026 Jun 28, 2026
Q1 FY2026 Mar 29, 2026
Q4 FY2025 Dec 28, 2025
Q3 FY2025 Sep 28, 2025
Q2 FY2025 Jun 29, 2025
Q1 FY2025 Mar 30, 2025
Q4 FY2024 Dec 29, 2024
Revenue
$618.9M
$630.9M
$619.8M
$723.6M
$699.9M
$613.9M
$692.8M
$707.8M
Cost of revenue
$329.3M
$358M
$356M
$403.2M
$364.3M
$339M
$349.5M
$381.7M
Gross profit
$289.6M
$272.9M
$263.8M
$320.4M
$335.6M
$274.9M
$343.3M
$326.1M
Selling, general and administrative
$182.7M
$189.7M
$199.3M
$194.4M
$186.9M
$178M
$187M
$187.5M
Research and development
$42.5M
$48.7M
$44.9M
$45.8M
$41.5M
$45.7M
$53.2M
$47.3M
Total operating expenses
$297.1M
$294.7M
$295.6M
$386.7M
$1.04B
$455.6M
$310.7M
$426.5M
Operating income
-$7.5M
-$21.8M
-$31.8M
-$66.3M
-$704.8M
-$180.7M
$32.6M
-$100.4M
Interest expense
-$55.4M
-$54.7M
-$51.1M
-$51M
-$46.1M
-$40.5M
-$40M
-$40.6M
Income before taxes
-$62.9M
-$81.2M
-$79.5M
-$112.4M
-$756.9M
-$229.6M
-$8.8M
-$140.9M
Income taxes
-$9.1M
$11.7M
$12.3M
$18.3M
-$23.9M
$25.8M
$3.9M
$37.5M
Net income
-$53.8M
-$92.9M
-$91.8M
-$130.7M
-$733M
-$255.4M
-$12.7M
-$178.4M
Net income attributable to common shareholders
-$53.8M
-$92.9M
-$91.8M
-$130.7M
-$733M
-$255.4M
-$12.7M
-$178.4M
EBITDA
$131.7M
$101.4M
$85.5M
$75.2M
$157.3M
$108.5M
$155.8M
$124.5M
Basic earnings per share
-$0.78
-$1.36
-$1.35
-$1.92
-$10.78
-$3.77
-$0.19
-$2.64
Diluted earnings per share
-$0.78
-$1.36
-$1.35
-$1.92
-$10.78
-$3.77
-$0.19
-$2.64
Recent news
Company coverage with links to the original publishers.
QuidelOrtho reported Q3 2026 earnings of $0.31 per share, beating consensus estimates of $0.18 by 72%, though revenues slightly missed expectations at $618.9M. Despite the earnings beat, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. The stock has underperformed the market by 50.9% year-to-date, and the Medical-Products industry ranks in the bottom 35% of Zacks industries.
QuidelOrtho Corporation (QDEL) shows strong Q2 2026 results with 21% adjusted EBITDA growth and expanding margins, supported by a diversified product portfolio and $50 million cost-saving initiatives through 2027. However, weak respiratory demand and overdependence on this segment pose risks, with the company adopting a cautious outlook for the 2026-2027 respiratory season.
The global lateral flow assay market is projected to grow from USD 10.84 billion in 2025 to USD 17.66 billion by 2035, with a 5.0% CAGR. Growth is driven by increased adoption of point-of-care testing, technological innovations including CRISPR-based assays, and the shift toward decentralized diagnostic models. Major players include Abbott, Roche, Siemens Healthineers, and Thermo Fisher Scientific, with infectious disease testing accounting for 72.2% of market share.
The global pregnancy detection kits market is projected to grow from USD 1.91 billion in 2025 to USD 2.69 billion by 2031, with a CAGR of 5.87%. Growth is driven by technological advancements enabling earlier detection, rising infertility rates, and increasing adoption of digital integration and e-commerce distribution. However, the market faces challenges from accuracy concerns and user error risks that erode consumer trust.
Rice Hall James & Associates purchased 574,877 shares of QuidelOrtho in Q4, increasing its stake to 833,791 shares valued at $23.8 million (1.3% of fund assets). The investment reflects confidence in the diagnostic technology company despite its stock being down 43.4% over the past year, as value investors anticipate improved financial results from recent leadership changes and strategic adjustments.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.